Crohn disease: epidemiology, diagnosis, and management
JD Feuerstein, AS Cheifetz - Mayo Clinic Proceedings, 2017 - Elsevier
Crohn disease is a chronic idiopathic inflammatory bowel disease condition characterized
by skip lesions and transmural inflammation that can affect the entire gastrointestinal tract …
by skip lesions and transmural inflammation that can affect the entire gastrointestinal tract …
Crohn's disease
J Torres, S Mehandru, JF Colombel, L Peyrin-Biroulet - The Lancet, 2017 - thelancet.com
Crohn's disease is a chronic inflammatory disease of the gastrointestinal tract, with
increasing incidence worldwide. Crohn's disease might result from a complex interplay …
increasing incidence worldwide. Crohn's disease might result from a complex interplay …
Multi-omics analyses of the ulcerative colitis gut microbiome link Bacteroides vulgatus proteases with disease severity
Ulcerative colitis (UC) is driven by disruptions in host–microbiota homoeostasis, but current
treatments exclusively target host inflammatory pathways. To understand how host …
treatments exclusively target host inflammatory pathways. To understand how host …
Edible ginger-derived nanoparticles: A novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer
There is a clinical need for new, more effective treatments for chronic and debilitating
inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. In this …
inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. In this …
Biologic agents for IBD: practical insights
S Danese, L Vuitton, L Peyrin-Biroulet - … reviews Gastroenterology & …, 2015 - nature.com
Six biologic agents are currently approved for the treatment of IBD: four anti-TNF agents
(infliximab, adalimumab, golimumab and certolizumab pegol) and two anti-integrin agents …
(infliximab, adalimumab, golimumab and certolizumab pegol) and two anti-integrin agents …
The real-world effectiveness and safety of vedolizumab for moderate–severe Crohn's disease: results from the US VICTORY Consortium
The Real-World Effectiveness and Safety of Vedolizumab for M... : Official journal of the American
College of Gastroenterology | ACG The Real-World Effectiveness and Safety of Vedolizumab for …
College of Gastroenterology | ACG The Real-World Effectiveness and Safety of Vedolizumab for …
[HTML][HTML] Plant-derived exosomes as a drug-delivery approach for the treatment of inflammatory bowel disease and colitis-associated cancer
Y Cai, L Zhang, Y Zhang, R Lu - Pharmaceutics, 2022 - mdpi.com
Inflammatory bowel disease (IBD) is a chronic recurrent intestinal disease and includes
Crohn's disease (CD) and ulcerative colitis (UC). Due to the complex etiology of colitis, the …
Crohn's disease (CD) and ulcerative colitis (UC). Due to the complex etiology of colitis, the …
Adalimumab monotherapy and a combination with azathioprine for Crohn's disease: a prospective, randomized trial
T Matsumoto, S Motoya, K Watanabe… - Journal of Crohn's …, 2016 - academic.oup.com
Abstract Background and Aims: The efficacy of azathioprine for Crohn's disease under
adalimumab treatment remains obscure. Methods: In an open-labelled prospective study …
adalimumab treatment remains obscure. Methods: In an open-labelled prospective study …
The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory …
P Kump, P Wurm, HP Gröchenig… - Alimentary …, 2018 - Wiley Online Library
Background Faecal microbiota transplantation is an experimental approach for the treatment
of patients with ulcerative colitis. Although there is growing evidence that faecal microbiota …
of patients with ulcerative colitis. Although there is growing evidence that faecal microbiota …
Predicting, preventing, and managing treatment-related complications in patients with inflammatory bowel diseases
L Beaugerie, JF Rahier, J Kirchgesner - Clinical Gastroenterology and …, 2020 - Elsevier
Risk of complications from specific classes of drugs for inflammatory bowel diseases (IBDs)
can be kept low by respecting contraindications. Patients with IBD frequently develop …
can be kept low by respecting contraindications. Patients with IBD frequently develop …